FISH abnormalities in Agent Orange–associated multiple myeloma.

Authors

null

Jeries Kort

University Hospitals Cleveland Medical Center/ Case Comprehensive Cancer Center, Cleveland, OH

Jeries Kort , Timothy O'Brien

Organizations

University Hospitals Cleveland Medical Center/ Case Comprehensive Cancer Center, Cleveland, OH, Cleveland VA Medical Center, Bay Village, OH

Research Funding

No funding received
None.

Background: Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic malignancies. Molecular investigations have identified a wide heterogeneity in MM at the genomic and epigenomic levels, often with IgH translocations and trisomies seen early in the pathogenesis. Etiological factors, though, are still not well characterized. Agent Orange (AO) was a herbicide widely used as a defoliant by the U.S. military during the Vietnam War. Studies have indicated a probable causative link between exposure to AO and the development of multiple myeloma; in fact, MM is now recognized by the VA as a service-connected diagnosis. However, there have been few small studies addressing whether there are any unique molecular findings in AO associated MM. We sought to determine if there were any specific myeloma FISH abnormalities seen in AO associated MM and if there were any differences in their respective survival. Methods: We included all patients diagnosed with MM from 2010-2022 at Louis Stokes VA Medical Center (Cleveland, OH). Data collected included: age, sex, race, year of diagnosis, AO exposure, bone marrow biopsy results and myeloma FISH panel results. We defined high risk MM based on the presence of t(14;16), t(14;20), del 17p/TP53 or gain 1q. Overall survival (OS) was calculated from date of diagnosis to death. Results: We included 162 patients with MM, among them 32 had AO exposure. There was no significant difference in age or race between exposed and non-exposed patients. MM FISH results were available for 137 patients. Overall, 20% of patients had high risk group cytogenetics and there was no significant difference based on AO exposure. However, there was a trend for increased TP53 mutations in those exposed to AO, although this did not reach statistical significance (8% vs. 3.6%, p = 0.3). Median OS was 72 months for non-exposed patients and 98 months for exposed patients, with no significant difference observed (p = 0.18). Conclusions: In this single institution, retrospective study, AO exposure was not associated with a higher incidence of high-risk cytogenetics by FISH in MM. There was a trend for increased TP53 mutation with AO exposure, but the cohort was small and did not reach statistical significance. In addition, AO exposure was not associated with a worse survival. Further studies are needed to clarify the effects of AO on the development of MM, including genomic and transcriptomic analysis to elucidate the pathobiology of this disease.

No AO
N = 130
AO Exposure,
N = 32
p-value
AGE68.58 (9.52)70.44 (3.44)0.091
SEX (M)129(99%)32(100%)> 0.9
RACE0.068
Black58(45%)8(25%)
White68(52%)24(75%)
MM FISH> 0.9
High Risk23(21%)5(20%)
Standard risk89(79%)20(80%)
Hyperdiploidy50(48%)13(52%)0.7
IgH Mutation0.3
t(11,14)13(12%)6(24%)0.12*
t(14,16)2(1.8%)1(4.0%)0.7*
t(4,14)7(6.4%)0(0%)
Other4(3.6%)0(0%)
13q del31(30%)7(29%)> 0.9
Tp53 or 17p Del4(3.6%)2(8.0%)0.3
1q Amp19(20%)5(22%)> 0.9

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e20056)

DOI

10.1200/JCO.2023.41.16_suppl.e20056

Abstract #

e20056

Abstract Disclosures

Similar Abstracts

First Author: Mateo Mejia Saldarriaga

First Author: David R. Braxton

First Author: Ting Deng